Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update

2026 Q3

Published 9 November 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer

BT-001 rectacl cancer

Published 5 November 2026
Categorized as 2026, 2026, BT-001, Invir.IO, Press release

Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery

SITC 2026 Abstract

Published 3 November 2026
Categorized as 2025, 2026, 2026, dates, Press release

Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026

SITC 2026

Published 5 October 2026
Categorized as 2025, 2026, 2026, dates, Press release

Transgene To Participate in Investor Access

Investor Access

Published 1 October 2026
Categorized as 2025, 2026, 2026, dates, Press release

Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field

2026 Half Year results

Published 24 September 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line

ProBioGen

Published 8 September 2026
Categorized as 2025, 2026, 2026, dates, Myvac, Press release

Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

NatCom

Published 2 September 2026
Categorized as 2025, 2026, dates, Press release

Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026

Mpox WCID

Published 25 June 2026
Categorized as 2025, 2026, dates, Press release

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

TG4070

Published 22 June 2026
Categorized as 2025, 2025, 2026, 2026, dates, Myvac, Press release

Posts pagination

Page 1 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu